"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
| Descriptor ID |
D057134
|
| MeSH Number(s) |
D12.776.124.486.485.114.244 D12.776.124.790.651.114.244 D12.776.377.715.548.114.244
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 5 | 7 |
| 2011 | 2 | 6 | 8 |
| 2012 | 6 | 6 | 12 |
| 2013 | 4 | 8 | 12 |
| 2014 | 7 | 10 | 17 |
| 2015 | 11 | 4 | 15 |
| 2016 | 11 | 13 | 24 |
| 2017 | 9 | 12 | 21 |
| 2018 | 16 | 10 | 26 |
| 2019 | 12 | 6 | 18 |
| 2020 | 18 | 16 | 34 |
| 2021 | 17 | 22 | 39 |
| 2022 | 6 | 40 | 46 |
| 2023 | 2 | 35 | 37 |
| 2024 | 12 | 11 | 23 |
| 2025 | 6 | 18 | 24 |
| 2026 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples. J Infect Dis. 2026 Mar 17; 233(3):e646-e650.
-
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials. Vaccine. 2026 Apr 02; 77:128380.
-
Structural basis for recognition of Rift Valley fever virus Gn protein by a human neutralizing monoclonal antibody with a kappa light chain. PLoS Pathog. 2026 Feb; 22(2):e1013926.
-
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clin Infect Dis. 2026 Jan 16; 81(Supplement_3):i6-i12.
-
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab. Clin Infect Dis. 2026 Jan 16; 81(Supplement_3):i13-i16.
-
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination. Vaccine. 2026 Jan 01; 69:127959.
-
Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity. J Virol. 2025 12 23; 99(12):e0125625.
-
Mouse-adapted SARS-CoV-2 Omicron BA.5 infection induces post-acute lung fibrosis in BALB/c mice. J Virol. 2025 11 25; 99(11):e0140625.
-
Ultrapotent human antibodies lock E protein dimers central region of diverse DENV3 morphological variants. Nat Commun. 2025 Oct 16; 16(1):9182.
-
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine. J Infect Dis. 2025 Oct 15; 232(4):971-981.